Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

Author: Scatena Caroline   Kumer Jeffrey   Arbitrario Jennifer   Howlett Anthony   Hawtin Rachael   Fox Judith   Silverman Jeffrey  

Publisher: Springer Publishing Company

ISSN: 0344-5704

Source: Cancer Chemotherapy and Pharmacology, Vol.66, Iss.5, 2010-10, pp. : 881-888

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content